Literature DB >> 12663879

Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

Francisco Marín1, Vanessa Roldán, Vicente Climent, Amaya Garcia, Pascual Marco, Gregory Y H Lip.   

Abstract

BACKGROUND AND
PURPOSE: Decreased matrix metalloproteinase-1 (MMP-1) and increased levels of its inhibitor, tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), reflect impaired matrix degradation with an increase in fibrosis. A prothrombotic state has been described in atrial fibrillation (AF), increasing the risk of stroke and thromboembolism. Because structural abnormalities and remodeling of atria have been observed in AF, we hypothesized that the prothrombotic state in AF may be related to abnormal indexes of matrix degradation.
METHODS: We studied 48 consecutive patients (30 men; age, 70.5+/-9.0 years) with chronic nonrheumatic AF who were not on anticoagulation. Plasma levels of MMP-1, TIMP-1, and prothrombin fragment 1+2 (F1+2, an index of thrombogenesis) were measured by enzyme-linked immunosorbent assay. M-mode, 2-dimensional, and Doppler echocardiographic studies were performed in all patients. Research indexes were compared with data from 32 control subjects in sinus rhythm who were of similar age and sex.
RESULTS: Patients with AF had lower levels of MMP-1 (P=0.011) but increased levels of TIMP-1 (P=0.033) and F1+2 (P<0.001) and a higher ratio of TIMP-1 to MMP-1 (P=0.009) compared with control subjects. After adjustment for sex, age, hypertension, and diabetes, TIMP-1 levels and the ratio of TIMP-1 to MMP-1 correlated with F1+2 levels (r=0.24, P=0.038; and r=0.26, P=0.023, respectively). In multivariate analysis, there was no independent relationship between MMP-1, TIMP-1, or ratio of TIMP-1 to MMP-1 and the presence of AF.
CONCLUSIONS: Patients with AF have evidence of impaired matrix degradation, but this was not independently associated with the presence of AF on multivariate analysis. However, an independent relationship was found between the MMP/TIMP system and prothrombotic state (assessed by F1+2 levels).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663879     DOI: 10.1161/01.STR.0000065431.76788.D9

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  15 in total

1.  Thrombophilia in ischemic stroke subtypes: implications for treatment.

Authors:  Cathy M Helgason
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

3.  Blood biomarkers in cardioembolic stroke.

Authors:  Teresa García-Berrocoso; Israel Fernández-Cadenas; Pilar Delgado; Anna Rosell; Joan Montaner
Journal:  Curr Cardiol Rev       Date:  2010-08

Review 4.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 5.  Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

6.  A clinical cardiology perspective of thrombophilias.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

7.  Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure.

Authors:  Rachael Deardorff; Francis G Spinale
Journal:  Biomark Med       Date:  2009-10-01       Impact factor: 2.851

8.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

9.  Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

10.  Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation.

Authors:  Andreas S Kalogeropoulos; Sotirios Tsiodras; Angelos G Rigopoulos; Eleftherios A Sakadakis; Andreas Triantafyllis; Dimitrios Th Kremastinos; Ioannis Rizos
Journal:  BMC Cardiovasc Disord       Date:  2011-12-28       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.